Display options
Cite
Yang X, Xu J, Wang R, et al. A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy. J Ophthalmol. 2016;2016:2473234doi: 10.1155/2016/2473234.
Yang, X., Xu, J., Wang, R., Mei, Y., Lei, H., Liu, J., Zhang, T., & Zhao, H. (2016). A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy. Journal of ophthalmology, 20162473234. https://doi.org/10.1155/2016/2473234
Yang, Xiaochun, et al. "A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy." Journal of ophthalmology vol. 2016 (2016): 2473234. doi: https://doi.org/10.1155/2016/2473234
Yang X, Xu J, Wang R, Mei Y, Lei H, Liu J, Zhang T, Zhao H. A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy. J Ophthalmol. 2016;2016:2473234. doi: 10.1155/2016/2473234. Epub 2016 Mar 13. PMID: 27034822; PMCID: PMC4808544.
Copy Download .nbib Format: NLM
Share it on

J Ophthalmol. 2016;2016:2473234. doi: 10.1155/2016/2473234. Epub 2016 Mar 13.

A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.

Journal of ophthalmology

Xiaochun Yang, Jianbiao Xu, Ruili Wang, Yan Mei, Huo Lei, Jun Liu, Ting Zhang, Haiyan Zhao

Affiliations

  1. Department of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.
  2. Department of General Surgery, The First People's Hospital of Yunnan Province, Yunnan 650032, China.
  3. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong 510062, China.

PMID: 27034822 PMCID: PMC4808544 DOI: 10.1155/2016/2473234

Abstract

Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned randomly to either preoperative IVC group or control group. Follow-up examinations were performed for three months after surgery. The primary bioactivity measures were severity of intraoperative bleeding, incidence of early and late recurrent VH, vitreous clear-up time, and best-corrected visual acuity (BCVA) levels. The secondary safety measures included intraocular pressure, endophthalmitis, rubeosis, tractional retinal detachment, and systemic adverse events. Results. The incidence and severity of intraoperative bleeding were significantly lower in IVC group than in the control group. The average vitreous clear-up time of early recurrent VH was significantly shorter in IVC group compared with that in control group. There was no significant difference in vitreous clear-up time of late recurrent VH between the two groups. Patients that received pretreatment of conbercept had much better BCVA at 3 days, 1 week, and 1 month after surgery than control group. Moreover, both patients with improved BCVA were greater in IVC group than in control group at each follow-up. Conclusions. Conbercept pretreatment could be an effective adjunct to vitrectomy in accelerating postoperative vitreous clear-up and acquiring stable visual acuity restoration for PDR.

References

  1. Eur Cytokine Netw. 2012 Oct-Dec;23(4):158-62 - PubMed
  2. J Biol Chem. 2005 Jan 21;280(3):2126-31 - PubMed
  3. PLoS One. 2008;3(11):e3554 - PubMed
  4. Exp Eye Res. 2014 May;122:102-9 - PubMed
  5. Retina. 2009 Jun;29(6):768-74 - PubMed
  6. Ophthalmology. 2004 Jun;111(6):1215-21 - PubMed
  7. Am J Ophthalmol. 2008 Oct;146(4):508-12 - PubMed
  8. Retina. 2015 Jan;35(1):69-74 - PubMed
  9. Mol Pharm. 2012 Dec 3;9(12):3422-33 - PubMed
  10. Arch Ophthalmol. 1990 Apr;108(4):595-7 - PubMed
  11. Retina. 2014 Jun;34(6):1177-81 - PubMed
  12. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):302-5 - PubMed
  13. Am J Ophthalmol. 2008 Aug;146(2):211-217 - PubMed
  14. Mol Vis. 2014 Jul 31;20:1109-21 - PubMed
  15. Ophthalmology. 2011 Nov;118(11):2218-26 - PubMed
  16. Br J Ophthalmol. 2005 Aug;89(8):1041-4 - PubMed
  17. Graefes Arch Clin Exp Ophthalmol. 2013 Sep;251(9):2131-9 - PubMed
  18. Exp Eye Res. 2012 Apr;97(1):154-9 - PubMed
  19. Clin Ophthalmol. 2011;5:697-704 - PubMed
  20. Ophthalmology. 2011 Apr;118(4):672-8 - PubMed
  21. Exp Eye Res. 2014 May;122:123-31 - PubMed
  22. Am J Ophthalmol. 2012 Oct;154(4):682-686.e2 - PubMed
  23. Biol Pharm Bull. 2011;34(12):1785-8 - PubMed
  24. Retina. 2006 Feb;26(2):149-52 - PubMed
  25. Int J Ophthalmol. 2013 Jun 18;6(3):316-20 - PubMed
  26. Mol Vis. 2008 Jan 10;14 :37-49 - PubMed
  27. Retina. 2011 Oct;31(9):1877-84 - PubMed
  28. Retina. 2004 Oct;24(5 Suppl):S3-19 - PubMed
  29. Eye (Lond). 2014 May;28(5):510-20 - PubMed
  30. J Res Med Sci. 2012 Sep;17(9):865-71 - PubMed

Publication Types